Corrigendum to “2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk” (Atherosclerosis (2019) 290 (140–205), (S0021915019314595), (10.1016/j.atherosclerosis.2019.08.014))

doi:10.1016/j.atherosclerosis.2019.12.004

Corrigendum to “2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk” (Atherosclerosis (2019) 290 (140–205), (S0021915019314595), (10.1016/j.atherosclerosis.2019.08.014))

, ,

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

Abstract

In row 4 of Table 3, ‘should’ should read as ‘may’; In 4.2.1, paragraph 3, ‘should’ should read ‘may’ to read ‘Overall, CAC score assessment with CT may be considered in individuals … ’ Also in the second row of ‘Recommendations for cardiovascular imaging for risk assessment of atherosclerotic cardiovascular disease,’ the Class should read ‘llb’; In the second paragraph of 7.5.2, ‘5–10 mg of monacolin K’ should read ‘2.5–10 mg’; and in the Key messages section, number 4, ‘ApoB may be a better measure of an individual's exposure to atherosclerotic lipoproteins' should read ‘ApoB may be a better measure of an individual's exposure to pro atherogenic lipoproteins'.

Original language	English
Pages (from-to)	80-82
Number of pages	3
Journal	Atherosclerosis
Volume	294
DOIs	https://doi.org/10.1016/j.atherosclerosis.2019.12.004
Publication status	Published - 1 Feb 2020

Keywords

guidelines
dyslipidaemia
cholesterol
triglycerides
low-density lipoproteins
high-density lipoproteins
apolipoprotein B
lipoprotein(a)
lipoprotein remnants
total cardiovascular risk
Treatment (lifestyle)
Treatment (drugs)
Treatment (adherence)
Very low-density lipoproteins
Familial hypercholesterolaemia

Access to Document

10.1016/j.atherosclerosis.2019.12.004

Fingerprint

Dive into the research topics of 'Corrigendum to “2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk” (Atherosclerosis (2019) 290 (140–205), (S0021915019314595), (10.1016/j.atherosclerosis.2019.08.014))'. Together they form a unique fingerprint.

1 Review article

2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk
The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC), 1 Jan 2020, In: European heart journal. 41, 1, p. 111-188 78 p.
Research output: Contribution to journal › Review article › peer-review

Cite this

@article{1561868509bf457da64efdb4240e12ac,

title = "Corrigendum to “2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk” (Atherosclerosis (2019) 290 (140–205), (S0021915019314595), (10.1016/j.atherosclerosis.2019.08.014))",

abstract = "In row 4 of Table 3, {\textquoteleft}should{\textquoteright} should read as {\textquoteleft}may{\textquoteright}; In 4.2.1, paragraph 3, {\textquoteleft}should{\textquoteright} should read {\textquoteleft}may{\textquoteright} to read {\textquoteleft}Overall, CAC score assessment with CT may be considered in individuals … {\textquoteright} Also in the second row of {\textquoteleft}Recommendations for cardiovascular imaging for risk assessment of atherosclerotic cardiovascular disease,{\textquoteright} the Class should read {\textquoteleft}llb{\textquoteright}; In the second paragraph of 7.5.2, {\textquoteleft}5–10 mg of monacolin K{\textquoteright} should read {\textquoteleft}2.5–10 mg{\textquoteright}; and in the Key messages section, number 4, {\textquoteleft}ApoB may be a better measure of an individual's exposure to atherosclerotic lipoproteins' should read {\textquoteleft}ApoB may be a better measure of an individual's exposure to pro atherogenic lipoproteins'.",

keywords = "guidelines, dyslipidaemia, cholesterol, triglycerides, low-density lipoproteins, high-density lipoproteins, apolipoprotein B, lipoprotein(a), lipoprotein remnants, total cardiovascular risk, Treatment (lifestyle), Treatment (drugs), Treatment (adherence), Very low-density lipoproteins, Familial hypercholesterolaemia",

author = "Francois Mach and Colin Baigent and Catapano, {Alberico L.} and Koskinas, {Konstantinos C.} and Manuela Casula and Lina Badimon and Chapman, {M. John} and {De Backer}, {Guy G.} and Victoria Delgado and Ference, {Brian A.} and Graham, {Ian M.} and Alison Halliday and Ulf Landmesser and Borislava Mihaylova and Pedersen, {Terje R.} and Gabriele Riccardi and Richter, {Dimitrios J.} and Sabatine, {Marc S.} and Taskinen, {Marja Riitta} and Lale Tokgozoglu and Olov Wiklund and Djamaleddine Nibouche and Zelveian, {Parounak H.} and Peter Siostrzonek and Ruslan Najafov and {van de Borne}, Philippe and Belma Pojskic and Arman Postadzhiyan and Lambros Kypris and Jind{\v r}ich {\v S}pinar and Larsen, {Mogens Lytken} and Eldin, {Hesham Salah} and Margus Viigimaa and Strandberg, {Timo E.} and Jean Ferrieres and Rusudan Agladze and Ulrich Laufs and Loukianos Rallidis and Laszlo Bajnok and Thorbjorn Gudjonsson and Vincent Maher and Yaakov Henkin and Gulizia, {Michele Massimo} and Aisulu Mussagaliyeva and Gani Bajraktari and Alina Kerimkulova and Gustavs Latkovskis and Omar Hamoui and Frank Visseren and Diederick Grobbee",

year = "2020",

month = feb,

day = "1",

doi = "10.1016/j.atherosclerosis.2019.12.004",

language = "English",

volume = "294",

pages = "80--82",

journal = "Atherosclerosis",

issn = "0021-9150",

publisher = "Elsevier",

}

Corrigendum to “2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk” (Atherosclerosis (2019) 290 (140–205), (S0021915019314595), (10.1016/j.atherosclerosis.2019.08.014)). /.
In: Atherosclerosis, Vol. 294, 01.02.2020, p. 80-82.

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

TY - JOUR

T1 - Corrigendum to “2019 ESC/EAS Guidelines for the management of dyslipidaemias

T2 - lipid modification to reduce cardiovascular risk” (Atherosclerosis (2019) 290 (140–205), (S0021915019314595), (10.1016/j.atherosclerosis.2019.08.014))

AU - Mach, Francois

AU - Baigent, Colin

AU - Catapano, Alberico L.

AU - Koskinas, Konstantinos C.

AU - Casula, Manuela

AU - Badimon, Lina

AU - Chapman, M. John

AU - De Backer, Guy G.

AU - Delgado, Victoria

AU - Ference, Brian A.

AU - Graham, Ian M.

AU - Halliday, Alison

AU - Landmesser, Ulf

AU - Mihaylova, Borislava

AU - Pedersen, Terje R.

AU - Riccardi, Gabriele

AU - Richter, Dimitrios J.

AU - Sabatine, Marc S.

AU - Taskinen, Marja Riitta

AU - Tokgozoglu, Lale

AU - Wiklund, Olov

AU - Nibouche, Djamaleddine

AU - Zelveian, Parounak H.

AU - Siostrzonek, Peter

AU - Najafov, Ruslan

AU - van de Borne, Philippe

AU - Pojskic, Belma

AU - Postadzhiyan, Arman

AU - Kypris, Lambros

AU - Špinar, Jindřich

AU - Larsen, Mogens Lytken

AU - Eldin, Hesham Salah

AU - Viigimaa, Margus

AU - Strandberg, Timo E.

AU - Ferrieres, Jean

AU - Agladze, Rusudan

AU - Laufs, Ulrich

AU - Rallidis, Loukianos

AU - Bajnok, Laszlo

AU - Gudjonsson, Thorbjorn

AU - Maher, Vincent

AU - Henkin, Yaakov

AU - Gulizia, Michele Massimo

AU - Mussagaliyeva, Aisulu

AU - Bajraktari, Gani

AU - Kerimkulova, Alina

AU - Latkovskis, Gustavs

AU - Hamoui, Omar

AU - Visseren, Frank

AU - Grobbee, Diederick

PY - 2020/2/1

Y1 - 2020/2/1

N2 - In row 4 of Table 3, ‘should’ should read as ‘may’; In 4.2.1, paragraph 3, ‘should’ should read ‘may’ to read ‘Overall, CAC score assessment with CT may be considered in individuals … ’ Also in the second row of ‘Recommendations for cardiovascular imaging for risk assessment of atherosclerotic cardiovascular disease,’ the Class should read ‘llb’; In the second paragraph of 7.5.2, ‘5–10 mg of monacolin K’ should read ‘2.5–10 mg’; and in the Key messages section, number 4, ‘ApoB may be a better measure of an individual's exposure to atherosclerotic lipoproteins' should read ‘ApoB may be a better measure of an individual's exposure to pro atherogenic lipoproteins'.

AB - In row 4 of Table 3, ‘should’ should read as ‘may’; In 4.2.1, paragraph 3, ‘should’ should read ‘may’ to read ‘Overall, CAC score assessment with CT may be considered in individuals … ’ Also in the second row of ‘Recommendations for cardiovascular imaging for risk assessment of atherosclerotic cardiovascular disease,’ the Class should read ‘llb’; In the second paragraph of 7.5.2, ‘5–10 mg of monacolin K’ should read ‘2.5–10 mg’; and in the Key messages section, number 4, ‘ApoB may be a better measure of an individual's exposure to atherosclerotic lipoproteins' should read ‘ApoB may be a better measure of an individual's exposure to pro atherogenic lipoproteins'.

KW - guidelines

KW - dyslipidaemia

KW - cholesterol

KW - triglycerides

KW - low-density lipoproteins

KW - high-density lipoproteins

KW - apolipoprotein B

KW - lipoprotein(a)

KW - lipoprotein remnants

KW - total cardiovascular risk

KW - Treatment (lifestyle)

KW - Treatment (drugs)

KW - Treatment (adherence)

KW - Very low-density lipoproteins

KW - Familial hypercholesterolaemia

UR - http://www.scopus.com/inward/record.url?scp=85076858833&partnerID=8YFLogxK

U2 - 10.1016/j.atherosclerosis.2019.12.004

DO - 10.1016/j.atherosclerosis.2019.12.004

M3 - Comment/Letter to the editor

AN - SCOPUS:85076858833

SN - 0021-9150

VL - 294

SP - 80

EP - 82

JO - Atherosclerosis

JF - Atherosclerosis

ER -

Corrigendum to “2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk” (Atherosclerosis (2019) 290 (140–205), (S0021915019314595), (10.1016/j.atherosclerosis.2019.08.014))

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Research output

2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk

Cite this